Skip to main content
Erschienen in: Current Allergy and Asthma Reports 3/2012

01.06.2012 | ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

Diagnostics and New Developments in the Treatment of Ocular Allergies

verfasst von: Osmo Kari, K. Matti Saari

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

About 30% of people suffer from allergic symptoms, and 40% to 80% of them have eye symptoms. Atopic conjunctivitis is divided into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. The treatment of seasonal allergic conjunctivitis is simple: antihistamines, anti-inflammatory agents, or cromoglycate. Perennial allergic conjunctivitis needs longer therapy with mast cell stabilizers and sometimes local steroids. Atopic keratoconjunctivitis requires long-term treatment of the lid eczema and keratoconjunctivitis. Vernal keratoconjunctivitis mainly affects children and young people. It commonly calms down after puberty. It demands intensive therapy, often for many years, to avoid serious complicating corneal ulcers. Giant papillary conjunctivitis is a foreign body reaction in contact lens users or patients with sutures following ocular surgery. Nonallergic eosinophilic conjunctivitis affects mostly middle-aged and older women with eosinophilic conjunctivitis and dry eye. Contact allergic blepharoconjunctivitis is often caused by cosmetics and eye medication. Work-related ocular allergies should be considered as a cause of resistant ocular symptoms in workplaces.
Literatur
1.
Zurück zum Zitat Key B. Allergy and allergic diseases. Part I N Engl J Med. 2001;344:30–7. Key B. Allergy and allergic diseases. Part I N Engl J Med. 2001;344:30–7.
2.
Zurück zum Zitat Ono SJ, Abelson MB. Allergic conjunctivitis update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–22.PubMedCrossRef Ono SJ, Abelson MB. Allergic conjunctivitis update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–22.PubMedCrossRef
3.
Zurück zum Zitat Hussain A, Awan H, Khan MD. Prevalence of non-vision-impairing conditions in a village in Chakwal district, Punjab, Pakistan. Ophthal Epidemiol. 2004;11(5):413–26.CrossRef Hussain A, Awan H, Khan MD. Prevalence of non-vision-impairing conditions in a village in Chakwal district, Punjab, Pakistan. Ophthal Epidemiol. 2004;11(5):413–26.CrossRef
4.
5.
Zurück zum Zitat Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153 Suppl 1:17–21.PubMedCrossRef Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153 Suppl 1:17–21.PubMedCrossRef
6.
Zurück zum Zitat •• Ibáñez MD, Garde JM. Allergy in patients under fourteen years of age in Alergológica 2005. J Investig Allergol Clin Immunol. 2009;19 Suppl 2:61–8. This is a good review of allergies in childhood.PubMed •• Ibáñez MD, Garde JM. Allergy in patients under fourteen years of age in Alergológica 2005. J Investig Allergol Clin Immunol. 2009;19 Suppl 2:61–8. This is a good review of allergies in childhood.PubMed
7.
Zurück zum Zitat Saari KM, Kari O, Haahtela T. Nonallergic eosinophilic conjunctivitis. Expert Rev Ophthalmol. 2007;2(3):331–3.CrossRef Saari KM, Kari O, Haahtela T. Nonallergic eosinophilic conjunctivitis. Expert Rev Ophthalmol. 2007;2(3):331–3.CrossRef
8.
Zurück zum Zitat •• Kari O, Haahtela T, Laine P, Turunen JP, Kari M, Sarna S, et al. Cellular characteristics of non-allergic eosinophilic conjunctivitis. Acta Ophthalmol Scand. 2010;88(2):245–50. This is the first article to characterize the cells typically found in NAEC. •• Kari O, Haahtela T, Laine P, Turunen JP, Kari M, Sarna S, et al. Cellular characteristics of non-allergic eosinophilic conjunctivitis. Acta Ophthalmol Scand. 2010;88(2):245–50. This is the first article to characterize the cells typically found in NAEC.
9.
Zurück zum Zitat •• Reitamo S, Remitz A, Haahtela T. Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy. 2009;64(4):503–4. This article points out the importance of early therapy to prevent chronicity and tissue damage.PubMedCrossRef •• Reitamo S, Remitz A, Haahtela T. Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy. 2009;64(4):503–4. This article points out the importance of early therapy to prevent chronicity and tissue damage.PubMedCrossRef
10.
Zurück zum Zitat Chigbu DI. The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye. 2009;32:3–15.PubMedCrossRef Chigbu DI. The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye. 2009;32:3–15.PubMedCrossRef
11.
Zurück zum Zitat Irani AM. Ocular mast cells and mediators. Immunol Allergy Clin North Am. 2008;28(1):25–42.PubMedCrossRef Irani AM. Ocular mast cells and mediators. Immunol Allergy Clin North Am. 2008;28(1):25–42.PubMedCrossRef
12.
Zurück zum Zitat Ikoma A. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci. 2009;110(3):265–9.PubMedCrossRef Ikoma A. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci. 2009;110(3):265–9.PubMedCrossRef
13.
Zurück zum Zitat • Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Clin Allergy Clin Immunol. 2011;11:420–7. This article describes the mechanisms of itch and new therapeutic modalities.CrossRef • Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Clin Allergy Clin Immunol. 2011;11:420–7. This article describes the mechanisms of itch and new therapeutic modalities.CrossRef
14.
Zurück zum Zitat •• Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively express multiple TH1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol. 2009;85(1):117–23. This paper shows present insight into the nature of preformed eosinophil cytokines and the functions of human eosinophils in mediating inflammation and initiation of specific immunity.PubMedCrossRef •• Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively express multiple TH1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol. 2009;85(1):117–23. This paper shows present insight into the nature of preformed eosinophil cytokines and the functions of human eosinophils in mediating inflammation and initiation of specific immunity.PubMedCrossRef
15.
Zurück zum Zitat • Mantelli F, Lambiase A, Bonini S, Bonini S. Clinical trials in allergic conjunctivitis: a systematic review. Allergy. 2011;66:919–24. This systematic review points out the lack of good controlled treatment studies.PubMedCrossRef • Mantelli F, Lambiase A, Bonini S, Bonini S. Clinical trials in allergic conjunctivitis: a systematic review. Allergy. 2011;66:919–24. This systematic review points out the lack of good controlled treatment studies.PubMedCrossRef
16.
Zurück zum Zitat Kari O, Salo OP, Halmepuro L, et al. Tear histamine during allergic conjunctivitis challenge. Graefe’s Arch Clin Exp Ophthalmol. 1985;223(2):60–2.CrossRef Kari O, Salo OP, Halmepuro L, et al. Tear histamine during allergic conjunctivitis challenge. Graefe’s Arch Clin Exp Ophthalmol. 1985;223(2):60–2.CrossRef
17.
Zurück zum Zitat Sacchetti M, Micera A, Lambiase A, Speranza S, Mantelli F, Petrachi G, et al. Tear levels of neuropeptides after specific allergen challenge in allergic conjunctivitis. Molecular Vision. 2011;17:47–52.PubMed Sacchetti M, Micera A, Lambiase A, Speranza S, Mantelli F, Petrachi G, et al. Tear levels of neuropeptides after specific allergen challenge in allergic conjunctivitis. Molecular Vision. 2011;17:47–52.PubMed
18.
Zurück zum Zitat Köberlein J, Kothe AC, Schaffert C. Determinants of patients compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:192–9.PubMedCrossRef Köberlein J, Kothe AC, Schaffert C. Determinants of patients compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:192–9.PubMedCrossRef
19.
Zurück zum Zitat • Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11:205–11. This article tells the well-known truth that there are no major differences among currently available antihistamines.PubMedCrossRef • Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11:205–11. This article tells the well-known truth that there are no major differences among currently available antihistamines.PubMedCrossRef
20.
Zurück zum Zitat Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27:623–31.PubMedCrossRef Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27:623–31.PubMedCrossRef
21.
Zurück zum Zitat Gous P, Ropo A. A comparison trial of the safety and efficacy of 0.1% percent pemiroplast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. Ocul Pharmacol Ther. 2004;20:139–50.CrossRef Gous P, Ropo A. A comparison trial of the safety and efficacy of 0.1% percent pemiroplast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. Ocul Pharmacol Ther. 2004;20:139–50.CrossRef
22.
Zurück zum Zitat Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660–6.PubMedCrossRef Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660–6.PubMedCrossRef
23.
Zurück zum Zitat Malling H-J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39(3):387–93.PubMedCrossRef Malling H-J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39(3):387–93.PubMedCrossRef
24.
Zurück zum Zitat •• Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64 Suppl 91:1–59. This article presents basic knowledge about sublingual immunotherapy.PubMed •• Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64 Suppl 91:1–59. This article presents basic knowledge about sublingual immunotherapy.PubMed
25.
Zurück zum Zitat Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011;6:CD007685. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011;6:CD007685.
26.
Zurück zum Zitat Yanni JM, Barney NP. Ocular allergy: clinical, therapeutic and drug discovery consideration. In: Yorio T, Clark A, Wax M, editors. Ocular therapeutics: eye on new discoveries. USA: Elsevier; 2008. Yanni JM, Barney NP. Ocular allergy: clinical, therapeutic and drug discovery consideration. In: Yorio T, Clark A, Wax M, editors. Ocular therapeutics: eye on new discoveries. USA: Elsevier; 2008.
27.
Zurück zum Zitat • Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol. 2009;9:477–81. This is a newer review about mechanisms in allergic eye diseases.PubMedCrossRef • Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol. 2009;9:477–81. This is a newer review about mechanisms in allergic eye diseases.PubMedCrossRef
28.
Zurück zum Zitat Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445–8.PubMedCrossRef Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445–8.PubMedCrossRef
29.
Zurück zum Zitat Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis; a retrospective study. Acta Ophtalmol. 2006;84(5):693–5.CrossRef Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis; a retrospective study. Acta Ophtalmol. 2006;84(5):693–5.CrossRef
30.
Zurück zum Zitat •• Remitz A, Virtanen HM, Reitamo S, Kari O. Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol. 2011;89(3)):e295–6. doi:10.1111/j.1755-3768.2009.01834.x. This is the first article to show how effective and safe tacrolimus ointment is in treating severe allergic eye disease.PubMed •• Remitz A, Virtanen HM, Reitamo S, Kari O. Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol. 2011;89(3)):e295–6. doi:10.​1111/​j.​1755-3768.​2009.​01834.​x. This is the first article to show how effective and safe tacrolimus ointment is in treating severe allergic eye disease.PubMed
31.
Zurück zum Zitat • Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–72. This article confirms the safety of topical cyclosporine drops in treatment of severe allergic eye diseases.PubMedCrossRef • Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–72. This article confirms the safety of topical cyclosporine drops in treatment of severe allergic eye diseases.PubMedCrossRef
32.
Zurück zum Zitat Kari O, Haahtela T. Is atopy a risk factor for the use of contact lenses? Allergy. 1992;47:295–8.PubMedCrossRef Kari O, Haahtela T. Is atopy a risk factor for the use of contact lenses? Allergy. 1992;47:295–8.PubMedCrossRef
33.
Zurück zum Zitat Kari O, Teir H, Huuskonen R, et al. Tolerance to different kinds of contact lenses in young atopic and non-atopic wearers. CLAO. 2001;27(3):151–4. Kari O, Teir H, Huuskonen R, et al. Tolerance to different kinds of contact lenses in young atopic and non-atopic wearers. CLAO. 2001;27(3):151–4.
34.
Zurück zum Zitat Kari O, Haahtela T. Conjunctival eosinophilia in atopic and non-atopic external eye symptoms. Acta Ophthalmol. 1992;70(3):335–40. Kari O, Haahtela T. Conjunctival eosinophilia in atopic and non-atopic external eye symptoms. Acta Ophthalmol. 1992;70(3):335–40.
35.
Zurück zum Zitat Ponikaus JU, Sherris DA, Kephart GM, et al. Features of airway remodelling and eosinophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2003;112(5):877–82.CrossRef Ponikaus JU, Sherris DA, Kephart GM, et al. Features of airway remodelling and eosinophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2003;112(5):877–82.CrossRef
36.
Zurück zum Zitat Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med. 1994;150(4):1038–48.PubMed Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med. 1994;150(4):1038–48.PubMed
37.
Zurück zum Zitat Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol. 1988;66(4):381–6. Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol. 1988;66(4):381–6.
38.
Zurück zum Zitat Feser A, Mahler V. Periorbital dermatitis: causes, differential diagnoses and therapy. J Dtsch Dermatol Ges. 2010;8(3):159–66.PubMedCrossRef Feser A, Mahler V. Periorbital dermatitis: causes, differential diagnoses and therapy. J Dtsch Dermatol Ges. 2010;8(3):159–66.PubMedCrossRef
39.
Zurück zum Zitat Peate WF. Work related eye injuries and illnesses. Am Family Phys. 2007;75(7):1017–22. Peate WF. Work related eye injuries and illnesses. Am Family Phys. 2007;75(7):1017–22.
40.
Zurück zum Zitat Peltonen S, Kari O, Jarva H, et al. Complement activation in tear fluid during occupational mold challenge. Ocul Immunol Inflamm. 2008;16(5):224–9.PubMedCrossRef Peltonen S, Kari O, Jarva H, et al. Complement activation in tear fluid during occupational mold challenge. Ocul Immunol Inflamm. 2008;16(5):224–9.PubMedCrossRef
41.
Zurück zum Zitat Kari O, Hannuksela M. Silmän yliherkkyyssairaudet. In: Haahtela T, Hannuksela M, Terho EO, editors. Allergologia. Helsinki: Kustannus Oy Duodecim; 1999. p. 203–13. Kari O, Hannuksela M. Silmän yliherkkyyssairaudet. In: Haahtela T, Hannuksela M, Terho EO, editors. Allergologia. Helsinki: Kustannus Oy Duodecim; 1999. p. 203–13.
42.
Zurück zum Zitat Kari O, Salo OP, Björkstén F, Backman A. Allergic conjunctivitis, total and specific IgE in the tear fluid. Acta Ophthalmol. 1985;63(1):97–9. Kari O, Salo OP, Björkstén F, Backman A. Allergic conjunctivitis, total and specific IgE in the tear fluid. Acta Ophthalmol. 1985;63(1):97–9.
43.
Zurück zum Zitat Löfstedt H, Westberg H, Seldén AI, Rublad S, Bryngelsson IL, Ngo Y, et al. Nasal and ocular effects in foundry workers using the hot box method. J Occup Environ Med. 2011;53:43–8.PubMedCrossRef Löfstedt H, Westberg H, Seldén AI, Rublad S, Bryngelsson IL, Ngo Y, et al. Nasal and ocular effects in foundry workers using the hot box method. J Occup Environ Med. 2011;53:43–8.PubMedCrossRef
Metadaten
Titel
Diagnostics and New Developments in the Treatment of Ocular Allergies
verfasst von
Osmo Kari
K. Matti Saari
Publikationsdatum
01.06.2012
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 3/2012
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-012-0252-9

Weitere Artikel der Ausgabe 3/2012

Current Allergy and Asthma Reports 3/2012 Zur Ausgabe

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

Nutrition and Asthma

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

Relevance of Birth Cohorts to Assessment of Asthma Persistence

ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

Migraine and Allergy: A Review and Clinical Update

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

The Role of Smoking in Allergy and Asthma: Lessons from the ECRHS

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.